RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
RIGL$43.91+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Income (Loss)
(In thousands)
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||||||
| · · 2024 · 2023 · 2022 | ||||||||||
| Net income (loss) | | $17,485 | | $(25,091) | | $(58,573) | | |||
| Other comprehensive income (loss): | | | | | | | | | | |
| Net unrealized gain (loss) on short-term investments | | 2 | | 161 | | (51) | | |||
| Comprehensive income (loss) | | $17,487 | | $(24,930) | | $(58,624) | | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.